elranatamab-bcmm injection 埃纳妥单抗

Drug introduction
Evantumab injection is a fully human bispecific antibody that targets both EGFR and MET. Abnormalities in the pathways of these two targets are an important cause of drug resistance in lung cancer patients. Evantumab injection activates immune cells through extracellular binding, exerts a synergistic anti-tumor effect with intracellular drugs, and mobilizes the immune system to fight tumors, bringing long-term benefits to patients. [1]
Category of action
Evantumab injection can be administered in combination with carboplatin and pemetrexed, and can be used as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer who have been confirmed to carry epidermal growth factor receptor (EGFR) exon 20 insertion mutations. [1]